Abstract
HIV-1 persists in a latent reservoir despite antiretroviral therapy (ART)1,2,3,4,5. This reservoir is the major barrier to HIV-1 eradication6,7. Current approaches to purging the latent reservoir involve pharmacologic induction of HIV-1 transcription and subsequent killing of infected cells by cytolytic T lymphocytes (CTLs) or viral cytopathic effects8,9,10. Agents that reverse latency without activating T cells have been identified using in vitro models of latency. However, their effects on latently infected cells from infected individuals remain largely unknown. Using a new ex vivo assay, we demonstrate that none of the latency-reversing agents (LRAs) tested induced outgrowth of HIV-1 from the latent reservoir of patients on ART. Using a quantitative reverse transcription PCR assay specific for all HIV-1 mRNAs, we demonstrate that LRAs that do not cause T cell activation do not induce substantial increases in intracellular HIV-1 mRNA in patient cells; only the protein kinase C agonist bryostatin-1 caused significant increases. These findings demonstrate that current in vitro models do not fully recapitulate mechanisms governing HIV-1 latency in vivo. Further, our data indicate that non-activating LRAs are unlikely to drive the elimination of the latent reservoir in vivo when administered individually.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295–1300 (1997).
Wong, J.K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291–1295 (1997).
Chun, T.W. et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94, 13193–13197 (1997).
Siliciano, J.D. et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9, 727–728 (2003).
Strain, M.C. et al. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc. Natl. Acad. Sci. USA 100, 4819–4824 (2003).
Richman, D.D. et al. The challenge of finding a cure for HIV infection. Science 323, 1304–1307 (2009).
Deeks, S.G. et al. Towards an HIV cure: a global scientific strategy. Nat. Rev. Immunol. 12, 607–614 (2012).
Karn, J. The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit. Curr. Opin. HIV AIDS 6, 4–11 (2011).
Choudhary, S.K. & Margolis, D.M. Curing HIV: pharmacologic approaches to target HIV-1 latency. Annu. Rev. Pharmacol. Toxicol. 51, 397–418 (2011).
Hakre, S., Chavez, L., Shirakawa, K. & Verdin, E. HIV latency: experimental systems and molecular models. FEMS Microbiol. Rev. 36, 706–716 (2012).
Archin, N.M. et al. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res. Hum. Retroviruses 25, 207–212 (2009).
Bartholomeeusen, K., Fujinaga, K., Xiang, Y. & Peterlin, B.M. Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription. J. Biol. Chem. 288, 14400–14407 (2013).
Contreras, X. et al. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J. Biol. Chem. 284, 6782–6789 (2009).
Shirakawa, K., Chavez, L., Hakre, S., Calvanese, V. & Verdin, E. Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol. 21, 277–285 (2013).
Doyon, G., Zerbato, J., Mellors, J.W. & Sluis-Cremer, N. Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog. AIDS 27, F7–F11 (2013).
Xing, S. et al. Disulfiram reactivates latent HIV-1 in a BCL-2–transduced primary CD4+ T cell model without inducing global T cell activation. J. Virol. 85, 6060–6064 (2011).
Banerjee, C. et al. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J. Leukoc. Biol. 92, 1147–1154 (2012).
Boehm, D. et al. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle 12, 452–462 (2013).
Li, Z., Guo, J., Wu, Y. & Zhou, Q. The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Res. 41, 277–287 (2013).
Zhu, J. et al. Reactivation of latent HIV-1 by inhibition of BRD4. Cell Reports 2, 807–816 (2012).
Korin, Y.D., Brooks, D.G., Brown, S., Korotzer, A. & Zack, J.A. Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J. Virol. 76, 8118–8123 (2002).
Kulkosky, J. et al. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 98, 3006–3015 (2001).
Williams, S.A. et al. Prostratin antagonizes HIV latency by activating NF-κB. J. Biol. Chem. 279, 42008–42017 (2004).
DeChristopher, B.A. et al. Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. Nat. Chem. 4, 705–710 (2012).
Kinter, A.L., Poli, G., Maury, W., Folks, T.M. & Fauci, A.S. Direct and cytokine-mediated activation of protein kinase C induces human immunodeficiency virus expression in chronically infected promonocytic cells. J. Virol. 64, 4306–4312 (1990).
Mehla, R. et al. Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS ONE 5, e11160 (2010).
Archin, N.M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482–485 (2012).
Blazkova, J. et al. Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4+ T cells from infected individuals receiving effective antiretroviral therapy. J. Infect. Dis. 206, 765–769 (2012).
Rasmussen, T.A., Tolstrup, M., Winckelmann, A., Ostergaard, L. & Sogaard, O.S. Eliminating the latent HIV reservoir by reactivation strategies: Advancing to clinical trials. Hum. Vacc. Immunother. 9, 790–799 (2013).
Spivak, A.M. et al. A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1–infected adults on antiretroviral therapy. Clin. Infect. Dis. 10.1093/cid/cit813 (12 December 2013).
Moriuchi, H., Moriuchi, M. & Fauci, A.S. Induction of HIV replication by allogeneic stimulation. J. Immunol. 162, 7543–7548 (1999).
Laird, G.M. et al. Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog. 9, e1003398 (2013).
Han, Y. et al. Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J. Virol. 78, 6122–6133 (2004).
Schröder, A.R. et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110, 521–529 (2002).
Baba, M., Miyake, H., Okamoto, M., Iizawa, Y. & Okonogi, K. Establishment of a CCR5-expressing T-lymphoblastoid cell line highly susceptible to R5 HIV type 1. AIDS Res. Hum. Retroviruses 16, 935–941 (2000).
Yang, H.C. et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J. Clin. Invest. 119, 3473–3486 (2009).
Shan, L. et al. A novel PCR assay for quantification of HIV-1 RNA. J. Virol. 87, 6521–6525 (2013).
Acknowledgements
We thank H. McHugh and A. Devadason for assistance with study participants. Funding was provided by the Martin Delaney Collaboratory of AIDS Researchers for Eradication and the Delaney AIDS Research Enterprise (US National Institutes of Health grants AI096113 and AI096109 (R.F.S.)), the Foundation for AIDS Research grants 108165-50-RGRL (R.F.S.) and 108707-54-RKRL (C.M.D.), the Johns Hopkins Center for AIDS Research (J.D.S.), US National Institutes of Health grant 43222 (R.F.S.) and the Howard Hughes Medical Institute (R.F.S.).
Author information
Authors and Affiliations
Contributions
G.M.L., C.K.B. and R.F.S. designed experiments; G.M.L. and C.K.B. performed experiments; C.M.D. obtained institutional review board approval and managed study participant recruitment; G.M.L., C.K.B., J.D.S. and R.F.S. analyzed the data and wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Table 1 and Supplementary Figures 1–3 (PDF 375 kb)
Rights and permissions
About this article
Cite this article
Bullen, C., Laird, G., Durand, C. et al. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 20, 425–429 (2014). https://doi.org/10.1038/nm.3489
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3489
This article is cited by
-
Bispecific antibodies promote natural killer cell-mediated elimination of HIV-1 reservoir cells
Nature Immunology (2024)
-
Potent latency reversal by Tat RNA-containing nanoparticle enables multi-omic analysis of the HIV-1 reservoir
Nature Communications (2023)
-
Learning from Persistent Viremia: Mechanisms and Implications for Clinical Care and HIV-1 Cure
Current HIV/AIDS Reports (2023)
-
Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections
Nature Communications (2023)
-
Reduced and highly diverse peripheral HIV-1 reservoir in virally suppressed patients infected with non-B HIV-1 strains in Uganda
Retrovirology (2022)